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Abstract
Objective To investigate the association between visit-to-visit variability
in blood pressure and cognitive function in old age (>70 years).
Design Prospective cohort study.
Setting PROSPER (PROspective Study of Pravastatin in the Elderly at
Risk) study, a collaboration between centres in Ireland, Scotland, and
the Netherlands.
Participants 5461 participants, mean age 75.3 years, who were at risk
of cardiovascular disease. Blood pressure was measured every three
months during an average of 3.2 years. Visit-to-visit variability in blood
pressure was defined as the standard deviation of blood pressure
measurements between visits.
Main outcome measures Four domains of cognitive function, testing
selective attention, processing speed, and immediate and delayed
memory. In a magnetic resonance imaging substudy of 553 participants,
structural brain volumes, cerebral microbleeds, infarcts, and white matter
hyperintensities were measured.
Results Participants with higher visit-to-visit variability in systolic blood
pressure had worse performance on all cognitive tests: attention (mean
difference high versus low thirds) 3.08 seconds (95% confidence interval
0.85 to 5.31), processing speed −1.16 digits coded (95% confidence
interval −1.69 to −0.63), immediate memory −0.27 pictures remembered
(95% confidence interval −0.41 to −0.13), and delayed memory −0.30
pictures remembered (95% confidence interval −0.49 to −0.11).
Furthermore, higher variability in both systolic and diastolic blood
pressure was associated with lower hippocampal volume and cortical
infarcts, and higher variability in diastolic blood pressure was associated
with cerebral microbleeds (all P<0.05). All associations were adjusted
for average blood pressure and cardiovascular risk factors.
ConclusionHigher visit-to-visit variability in blood pressure independent
of average blood pressure was associated with impaired cognitive
function in old age.
Introduction
Visit-to-visit variability in blood pressure independent of
average blood pressure is related to cerebrovascular damage.1
It has been shown that higher blood pressure variability increases
the risk of stroke and that antihypertensives, which decrease
both variability in blood pressure and mean blood pressure,
more effectively reduce the risk of stroke.2 In addition,
observational studies have shown associations of variability in
blood pressure, independent of average blood pressure, with
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white matter hyperintensities, carotid artery intima media
thickness, and atherosclerosis in older people (≥55 years).3-5
The relation between increased variability in blood pressure and
end organ damage is well established.6Recent evidence indicates
that higher visit-to-visit variability is linked with microvascular
damage, endothelial injury, and disturbances in vascular smooth
muscle functioning.7 8 Indicators of cerebral small vessel disease,
including white matter hyperintensities, cortical microinfarcts,
and cerebral microbleeds are implicated in the pathogenesis of
cognitive impairment.9-11 Several pathological, observational,
and experimental studies have shown that disruption of the
blood-brain barrier due to microvascular damage results in
neuronal injury and accelerates neuronal loss and brain atrophy.12
Hence higher variability in blood pressure might potentially
lead to cognitive impairment through changes in the brain
structures and development of cerebral small vessel disease.
We investigated the association of variability in blood pressure
between visits independent of average blood pressure with
cognitive function in older participants (>70 years) at high risk
of cardiovascular disease. Additionally, we investigated possible
explanations behind this association in a magnetic resonance
imaging substudy.
Methods
Study design and participants
The data in this study were obtained from PROSPER (The
PROspective Study of Pravastatin in the Elderly at Risk), a
randomised, double blind, placebo controlled trial designed to
investigate the effect of pravastatin in the prevention of vascular
events in elderly people with pre-existing, or risk factors for,
cardiovascular disease. This trial included 5804 people aged
70-82 years who were enrolled from three collaborating centres
in Ireland, Scotland, and the Netherlands. Approximately 50%
of the participants showed evidence of cardiovascular disease,
including stable angina, intermittent claudication, stroke (the
type, haemorrhagic or ischaemic, was unknown), transient
ischaemic attack, myocardial infarction, and vascular surgery.
The rest of the participants had one or moremajor cardiovascular
risk factors, defined as hypertension, cigarette smoking, or
diabetes mellitus. The primary outcome of the study was the
combined endpoint of definite or suspected death from coronary
heart disease, non-fatal myocardial infarction, and fatal or
non-fatal stroke during a mean follow-up of 3.2 years. In the
present study we included 5461 participants for whom data on
variability in blood pressure and cognitive function were
available. Additionally, participants from the Netherlands were
invited to participate in a magnetic resonance imaging substudy.
Participants were included from both the pravastatin and the
placebo groups as we previously reported that treatment with
pravastatin did not influence cognitive function, structural brain
volumes, or indicators of cerebral small vessel disease.13-15
Blood pressure measurements
We measured systolic and diastolic blood pressure at baseline
and every three months. Blood pressure was measured with
participants in the sitting position and using a fully automatic
electronic sphygmomanometer (OmronM4, Kyoto, Japan). All
measurements were performed in the same clinical setting. In
the analyses we used the average values of these blood pressure
measurements. We defined visit-to-visit variability in blood
pressure as the standard deviation of blood pressure
measurements during the study period.We report the variability
in blood pressure using only the standard deviation. Variance
and coefficient of variation, which are two other measures of
variability, are strongly correlated with the standard deviation
(see supplementary table S-1) and they showed similar
associations with cognitive and magnetic resonance imaging
outcomes (data not shown).
Cognitive function
The mini-mental state examination was used to evaluate global
cognitive function at baseline; to exclude participants with poor
cognitive function at baseline we used a cut-off score of 24
points or more (out of 30) as an inclusion criterion. In the present
study we used data on cognitive function assessed at the end of
the study, after a mean follow-up of 3.2 years, by a cognitive
test battery consisting of four different tests. The Stroop colour
and word test was used to assess selective attention and reaction
time. The participants were asked to read the name of a colour,
which appeared in a colour different from that being named.
The outcome variable was the total number of seconds to
complete the test; a higher score indicating worse performance.
General cognitive speed was tested by the letter-digit coding
test. The participants had to match certain digits with letters
according to a provided key. The outcome variable was the total
number of correct entries in 60 seconds, with higher scores
indicating better performance. The picture-word learning test
was used to assess immediate and delayed memory. The
participants were shown 15 pictures and were then asked to
recall as many pictures as possible in three trials. After 20
minutes they were asked to repeat the test to measure their
delayed recall. The outcome variable was the accumulated
number of correct recalled pictures, immediately and after 20
minutes, with higher scores indicating better performance.
Detailed descriptions of the cognitive tests and the procedures
have been published previously.16
Magnetic resonance imaging substudy
Overall, 646 of the 1100 Dutch participants in the PROSPER
study consented to participate in themagnetic resonance imaging
substudy. Forty of the 646 original study participants died during
the follow-up period. Magnetic resonance imaging was
performed at the end of the follow-up period in the remaining
606 participants. Data on visit-to-visit variability in blood
pressure and magnetic resonance imaging were available for
553 participants. Details of individual variables of magnetic
resonance imaging scanning have been published previously.13
All imaging was performed on a magnetic resonance system
operating at a field strength of 1.5 Tesla (Philips Medical
Systems, Best, Netherlands). We used the SIENAX technique
to calculate grey and white matter volumes. In short, SIENAX
starts by extracting brain and skull images from input data for
the whole head. The brain image is then affine registered to
Montreal Neurological Institute 152 space (by using the skull
image to determine the registration scaling), done primarily to
obtain the volumetric scaling factor to be used as normalisation
for head size. Next we carried out tissue type segmentation with
partial volume estimation to calculate the total volume of brain
tissue (including separate estimates of volumes of grey matter,
white matter, peripheral grey matter, and ventricular
cerebrospinal fluid).17 The algorithm FIRST (the Oxford Centre
for Functional MRI of the Brain’s (FMRIB) integrated
registration and segmentation tool) was applied to estimate the
volume of hippocampus. In addition, we estimated the volume
of six other subcortical regions, including nucleus accumbens,
globus pallidus, amygdala, putamen, caudate nucleus, and
thalamus. FIRST is part of FSL (FMRIB’s software library)
and performs both registration and segmentation of the
mentioned subcortical regions.18 To assess cerebral microbleeds,
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two experienced raters blinded to the participants’ clinical
history read all the magnetic resonance imaging scans in
consensus. Cerebral microbleeds were defined as focal areas of
signal loss on T2 weighted gradient echo pulse sequence
(“blooming effect”) that were invisible or smaller on T2
weighted magnetic resonance imaging.19. For each participant
we recorded the number and location (cortical, subcortical, and
infratentorial) of the cerebral microbleeds. Segmentation of
white matter hyperintensities volume was performed
automatically using software for Neuro-Image Processing in
Experimental Research (SNIPER), an in-house developed
program for image processing.20 This segmentation was based
on the T2 weighted and fluid attenuated inversion recovery
(FLAIR) images. Cerebral infarcts were defined as parenchymal
defects seen on FLAIR images with the same signal intensity
as cerebrospinal fluid and a surrounding rim of high signal
intensity after a vascular distribution.
Personal and clinical characteristics
We recorded the personal, medical, and anthropometric data of
the participants at baseline. A fasting venous blood sample was
taken for biochemical and haematological assessment. Western
blotting was used on the plasma samples to determine
apolipoprotein E epsilon 2/3/4 phenotype.21
Statistical analysis
Characteristics of the study participants are reported as mean
(standard deviation) for continuous variables and frequency
(percentage) for categorical variables. We used Pearson’s
correlation coefficient to calculate the correlation between
variability in blood pressure and average blood pressure. Linear
regression models were used to assess the association of
variability in blood pressure and average blood pressure with
cognitive function. Dependent variables were the mean scores
of the cognitive tests. In the tables these scores are presented in
thirds of systolic and diastolic blood pressure and blood pressure
variability. In the magnetic resonance imaging substudy, we
used logistic regression models to estimate the odds ratio and
95% confidence interval of the presence of microbleeds or
infarcts in different thirds of blood pressure variability as well
as average blood pressure. We used multivariable linear
regression models to test the association between blood pressure
variability and average blood pressure with volume of white
matter hyperintensities and structural brain volumes. P values
in all analyses were calculated using systolic and diastolic blood
pressure variability as continuous variables.
We performed our analyses in three steps. In the first step, we
carried out crude analyses, in which we only adjusted for
cognitive test version where appropriate. In the second step, we
added age, sex, education, and country as covariates to
investigate the potential influence of these factors on the
associations (model 1). In the final model (model 2), we further
adjusted the analyses for the following potential confounders:
cardiovascular diseases and risk factors (history of vascular
disease, history of hypertension, history of diabetes mellitus,
smoking status, cholesterol levels, body mass index), average
blood pressure, statin treatment, and apolipoprotein E genotype.
We adjusted the analyses of systolic blood pressure variability
with cognitive function and magnetic resonance imaging
outcomes for average systolic blood pressure. The analyses of
variability in diastolic blood pressure with cognitive function
and magnetic resonance imaging outcomes were adjusted for
average diastolic blood pressure. Since the associations did not
essentially change in different models, results of the second
model are presented in the manuscript and results from the other
models are presented in the supplementary file (tables S-2 and
S-3). All analyses were performed using SPSS software (version
20.0.0).
Results
Table 1⇓ shows the characteristics of the participants in the
whole group and in the magnetic resonance imaging substudy.
Blood pressure was measured in an average number of 12.7
visits in the whole group and 12.9 visits in the magnetic
resonance imaging substudy. Average systolic and diastolic
blood pressure over the period of blood pressure measurements
were 153.1 mm Hg and 82.5 mm Hg, respectively. The
correspondingmean standard deviation values during this period
were 14.8 mm Hg and 7.1 mm Hg.
There was a weak but significant correlation between average
systolic blood pressure and standard deviation of systolic blood
pressuremeasurements (r=0.20, P<0.001). Similarly, the average
diastolic blood pressure was weakly but significantly correlated
with the standard deviation of diastolic blood pressure
measurements (r=0.12, P<0.001).
Table 2⇓ shows the association of visit-to-visit variability in
systolic and diastolic blood pressure with cognitive function.
Higher variability was associated with worse performance on
the Stroop test (both P<0.001), letter-digit coding test (both
P<0.001), immediate picture-word learning test (both P<0.001),
and delayed picture-word learning test (both P=0.001). All
associations were independent of average blood pressure and
cardiovascular diseases and risk factors, as all analyses were
adjusted for these factors. The figure⇓ presents the mean
cognitive scores (95% confidence intervals) in each third of
systolic and diastolic blood pressure variability. Data on the
association of blood pressure variability with cognitive function
from crude and minimally adjusted models are shown in the
supplementary file (tables S-2 and S-3). Furthermore, we found
a significant association of higher average systolic and diastolic
blood pressure with worse performance in different domains of
cognitive function (all P<0.05), except for the association
between higher average systolic blood pressure and performance
on the picture-word learning tests (P>0.05) (see supplementary
table S-4).
Table 3⇓ shows the association of visit-to-visit variability in
systolic and diastolic blood pressure with structural brain
volumes. Higher variability was associated with lower
hippocampal volume (both P=0.01). There was no association
between blood pressure variability and volume of the other brain
structures (all P>0.05), except for the association between higher
variability in systolic blood pressure and lower amygdala and
putamen volumes (both P=0.04). Analyses were adjusted for
average systolic and diastolic blood pressures, which themselves
were not associated with structural brain volumes (all P>0.05)
(see supplementary table S-5).
Table 4⇓ shows the association between visit-to-visit variability
in blood pressure and cerebral microbleeds, infarcts, and white
matter hyperintensities. Higher variability in systolic and
diastolic blood pressure was associated with a higher risk of
cortical infarcts (both P=0.02). Prevalence of cortical infarcts
in participants with low, middle, and high variability in systolic
blood pressure was 9.2%, 12.0%, and 16.2%, respectively.
Prevalence of cortical infarcts in participants with low, middle,
and high variability in diastolic blood pressure was 7.9%, 13.3%,
and 16.2%, respectively. Furthermore, higher variability in
diastolic blood pressure was associated with a higher risk of all
types of microbleeds (P=0.01) as well as subcortical microbleeds
(P=0.004). Prevalence of microbleeds in participants with low,
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middle, and high variability in systolic blood pressure was
21.2%, 23.9%, and 28.4%, respectively. Prevalence of cortical
infarcts in participants with low, middle, and high variability
in diastolic blood pressure was 17.8%, 27.5%, and 28.9%,
respectively. Variability in systolic and diastolic blood pressure
was not associated with white matter hyperintensities (both
P>0.05). We found no association of average systolic and
diastolic blood pressure with cerebral microbleeds, infarcts, and
white matter hyperintensities (all P>0.05) (see supplementary
table S-6).
We performed four sensitivity analyses to explore whether the
association of visit-to-visit variability in blood pressure with
the studied outcomes could be affected by participants with a
history of clinical stroke or transient ischaemic attack (n=606)
and cardiovascular disease (n=2404), participants with new or
a change in antihypertensive therapy during the study period
(n=2733), participants who developed vascular events (n=872)
or arrhythmia (n=506) during the study period, and participants
with a high average blood pressure (defined as average systolic
blood pressure of ≥140 mm Hg and diastolic blood pressure of
≥80mmHg during the study period) (n=830). These sensitivity
analyses showed that the results did not materially change. In
an overall sensitivity analysis we excluded all participants with
the aforementioned conditions (n=4654) and the results remained
essentially unchanged (data not shown).
Discussion
Higher visit-to-visit variability in systolic and diastolic blood
pressure was associated with worse performance in different
domains of cognitive function and lower hippocampal volume
and risk of cortical infarcts. Higher variability in diastolic blood
pressure was associated with risk of cerebral microbleeds. These
associations were independent of various cardiovascular risk
factors, in particular average systolic and diastolic blood
pressures.
Although hypertension is a well established risk factor for
cardiovascular diseases,22 increasing evidence indicates that the
predictive value of conventional blood pressure measurement
for cardiovascular diseases attenuates with increasing age.23 24
Recent studies have shown that higher visit-to-visit variability
in blood pressure increases the risk of cardiovascular events,25
stroke,11 24 and carotid artery atherosclerosis26 in older people,
independent of average blood pressure. Given the link between
neurovascular dysfunction and cognitive impairment,27 a recent
study on 201 elderly participants (mean age 79.9 years) at high
risk of cardiovascular disease showed that high visit-to-visit
variability in blood pressure during 12 months was associated
with worse performance in the mini-mental state examination
and global deterioration scale.28Consistent with this finding, by
using a population of over 5000 participants and over three years
of blood pressure measurements, we showed that high
visit-to-visit variability in both systolic and diastolic blood
pressure was associated with worse performance in different
domains of cognitive function, including selective attention,
processing speed, immediate verbal memory, and delayed
memory.
The magnitude of associations in this study, reflected as
differences in cognitive scores between top and bottom thirds
of variability in systolic and diastolic blood pressure, are
comparable with the observed differences in cognitive function
between groups of apolipoprotein E genotype on cognitive
function.29 The apolipoprotein E4 genotype is a well recognised
risk factor for the development of dementia in later life and it
has been shown that people who carry this risk factor have a
four times higher risk of developing late onset Alzheimer’s
disease.30 Similar differences in cognitive test scores in
apolipoprotein E groups and variability in blood pressure implies
that the observed associations can be considered clinically
relevant.
Different explanations can be proposed for the observed
association between high visit-to-visit variability in blood
pressure and impaired cognitive function. Firstly, both blood
pressure variability and cognitive impairment could stem from
a common cause, without themselves being causally related.
Cardiovascular risk factors are the most likely candidate.31
Nevertheless, we reported our analyses adjusted for different
cardiovascular risk factors and we performed a sensitivity
analysis, by separately excluding those with a history of
cardiovascular diseases. This did not change our estimates,
althoughwe accept that residual confounding could remain from
unmeasured risk factors for cardiovascular disease. As a second
explanation, high visit-to-visit variability in blood pressure
might reflect a long term haemodynamic instability in the
systemic circulation that puts stress on the vascular
endothelium.7 32 This haemodynamic stress may lead to
endothelial dysfunction and microvascular damage with
consequent alterations in brain structure and function.33 Thirdly,
exaggerated fluctuations in systemic blood pressure could result
in repeated episodes of cerebral hypoperfusion causing neuronal
injury and cell death, particularly in vulnerable brain regions
such as the hippocampus.4 In line with latter explanations, we
found that higher visit-to-visit variability in blood pressure is
related to lower hippocampal volume and the presence of
cerebral microbleeds and cortical infarcts. Given the well
described association of hippocampal atrophy34 and cerebral
small vessel disease10 with cognitive impairment, our findings
may suggest that decreased hippocampal volume, cerebral
microbleeds, and cortical infarcts are potential pathogenic
mechanisms behind the association between variability in blood
pressure and cognitive impairment.
Current evidence on the association of variability in blood
pressure with structural brain damage and cerebral small vessel
disease mainly comes from studies that focused on variability
in ambulatory blood pressure rather than visit-to-visit variability.
These studies showed that higher variability in ambulatory blood
pressure is associated with brain atrophy and white matter
lesions.35-37 In the present study, we only observed the association
of visit-to-visit variability in blood pressure with lower
hippocampal volume, cerebral microbleeds, and cortical infarcts.
This might imply that different measures of blood pressure
variability carry different predictive values for brain outcomes.24
Data on the association between visit-to-visit variability in blood
pressure and manifestations of small vessel diseases are scarce.
Consistent with our findings, a recent study showed that higher
visit-to-visit variability in blood pressure in people with a history
of ischaemic stroke was associated with progression of cerebral
microbleeds but not with white matter lesions.38 It is, however,
still unclear whether higher variability in blood pressure is a
cause or consequence of brain disease. It has been suggested
that higher variability itself could originate from previously
established brain diseases disturbing central autonomic control.39
While clinical trials have shown conflicting findings on the
benefit of antihypertensive therapy on reducing the risk of
dementia, calcium channel blockers, the most effective drug
class to reduce variability in blood pressure,40 showed significant
efficacy in lowering the risk of vascular cognitive impairment.41
This might highlight potential clinical implications of agents
reducing blood pressure variability in lowering the risk of brain
vascular disease and cognitive impairment in old age.
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Collectively, we are not able to make a causal inference from
our observation, and future long term investigations are
warranted to examine whether strategies to reduce variability
in blood pressure can effectively decrease the risk of cognitive
impairment as well as of brain vascular disease.
Strengths and limitations of this study
The major strengths of this study include a large sample size
and application of an extended standardised cognitive test battery
to assess cognitive function. In addition, availability of
neuroimaging data provided us with a unique opportunity to
investigate potential biological pathways linked to the
association between variability in blood pressure and cognitive
function. However, this study has certain limitations. Firstly,
we included elderly participants at risk of cardiovascular
diseases with relatively preserved cognitive function
(mini-mental state examination ≥24 points), which might limit
the extrapolation of our findings to a general elderly population.
However, this restriction has possibly resulted in a homogeneous
study population who are among the main target groups for
preventing cognitive decline.42 Secondly, the outcomes of this
study were evaluated at one time point, and long term
longitudinal studies are needed to test whether lowering
variability in blood pressure could lead to decelerated cognitive
decline and lower the burden of brain diseases. Thirdly, owing
to the limited number of participants in the magnetic resonance
imaging substudy, we had limited power in several outcome
measures. This means that the absence of significant associations
for several outcomemeasures should be interpreted with caution.
There are reports indicating that higher visit-to-visit variability
in blood pressure is related to a higher risk of stroke and
cerebrovascular damage,1 however, the exactmechanisms behind
these associations are still unclear. This problem needs to be
addressed in future magnetic resonance imaging studies with
larger numbers of participants. Fourthly, although we adjusted
our analyses for different potential confounding factors, some
other confounders may exist that we did not consider in our
analyses. Future studies investigating the determinants of
visit-to-visit variability in blood pressure might help to
understand better the association between variability in blood
pressure and neurocognitive outcomes.
Conclusions
In conclusion, our findings suggest that higher visit-to-visit
variability in blood pressure independent of average blood
pressure is associated with worse cognitive performance in older
people at high risk of cardiovascular disease. Changes in
hippocampal volume and occurrence of cortical infarcts and
cerebral microbleedsmight be candidate pathogenicmechanisms
behind this association. This observation merits further
interventional studies to determine whether reducing variability
in blood pressure can decrease the risk of cognitive impairment
in old age.
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Tables
Table 1| Characteristics of study participants in whole group andmagnetic resonance imaging (MRI) substudy. Values are means (standard
deviations) unless stated otherwise
MRI substudy (n=553)Whole group (n=5461)Characteristics
12.9 (1.5)12.7 (2.4)No of visits
74.9 (3.2)75.3 (3.3)Age (years)
241 (43.6)2822 (51.7)No (%) women
15.5 (2.9)15.1 (2.1)Age left school (years)
No (%) with vascular risk factors:
341 (63.1)3399 (62.2)History of hypertension
91 (16.5)576 (10.5)History of diabetes mellitus
89 (16.1)606 (11.1)History of stroke or transient ischaemic attack
67 (12.1)714 (13.1)History of myocardial infarction
240 (43.4)2404 (44.0)History of vascular disease
115 (20.8)1433 (26.2)Current smoker
26.7 (3.6)26.9 (4.2)Body mass index
5.7 (0.8)5.7 (0.9)Total cholesterol level
Blood pressure (mm Hg):
156.1 (16.4)153.1 (16.1)Systolic*
85.1 (7.3)82.5 (7.5)Diastolic*
13.9 (4.6)14.8 (5.0)Variability in systolic†
7.4 (2.3)7.1 (2.9)Variability in diastolic†
Cognitive function‡:
56.9 (23.3)69.4 (31.6)Stroop test score (seconds)
26.3 (7.4)21.8 (8.0)Letter-digit coding test score (digits coded)
Picture-word learning test (pictures remembered):
10.1 (2.2)9.2 (2.2)Immediate recall score
11.1 (3.0)9.8 (3.1)Delayed recall score
MRI features:
590 (44)—Grey matter (mL)
768 (38)—White matter (mL)
7.5 (1.1)—Hippocampus (mL)
124 (24.0)—No (%) with microbleeds
180 (33.6)—No (%) with infarcts
65 (12.1)—Cortical
112 (21.0)—Lacunar
7.2 (1.1)—White matter hyperintensity volume (mL)
*Mean of all blood pressure measurements during follow-up.
†Standard deviation of all blood pressure measurements during follow-up.
‡Cognitive test score at end of follow-up.
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Table 2| Cognitive function in thirds of visit-to-visit blood pressure variability. Values are means (standard errors) unless stated otherwise
P valueThird of visit-to-visit blood pressure variabilityVariables
High (n=1820)Middle (n=1821)Low (n=1820)
Systolic blood pressure
—16.3-64.412.3-16.20.7-12.2Range of SD (mm Hg)
<0.00171.54 (0.82)68.75 (0.79)68.46 (0.79)Stroop test score (seconds)
<0.00121.24 (0.19)21.82 (0.19)22.40 (0.19)Letter-digit coding test score (digits coded)
Picture-word learning test (pictures
remembered):
<0.0019.10 (0.05)9.28 (0.05)9.37 (0.05)Immediate recall score
0.0019.70 (0.08)9.89 (0.07)10.00 (0.07)Delayed recall score
Diastolic blood pressure
—8.6-33.16.6-8.50-6.5Range of SD (mm Hg)
<0.00171.34 (0.80)68.89 (0.79)68.28 (0.79)Stroop test score (seconds)
<0.00121.27 (0.19)21.93 (0.19)22.35 (0.19)Letter-digit coding test score (digits coded)
Picture-word learning test (pictures
remembered):
<0.0019.13 (0.05)9.22 (0.05)9.41 (0.05)Immediate recall score
0.0019.74 (0.07)9.88 (0.07)10.01 (0.07)Delayed recall score
Analyses adjusted for age, sex, body mass index, statin treatment, apolipoprotein E genotype, country, education, test version where appropriate, smoking,
cholesterol level, history of vascular diseases, history of hypertension, history of diabetes mellitus, and average blood pressure measures.
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Table 3| Structural brain volumes in three groups of visit-to-visit blood pressure variability. Values are means (standard errors) (mL) unless
stated otherwise
P valueThird of visit-to-visit blood pressure variabilityVariables
HighMiddleLow
(n=149)(n=210)(n=194)Systolic blood pressure
—16.3-64.412.3-16.20.7-12.2Range of SD (mm Hg)
0.21589 (3)590 (3)593 (3)Grey matter
0.19765 (3)770 (3)770 (3)White matter
0.017.4 (0.08)7.6 (0.07)7.6 (0.07)Hippocampus
(n=191)(n=184)(n=178)Diastolic blood pressure
—8.6-33.16.6-8.50-6.5Range of SD (mm Hg)
0.18587 (3)594 (3)591 (3)Grey matter
0.62764 (3)772 (3)768 (3)White matter
0.017.4 (0.07)7.5 (0.07)7.6 (0.07)Hippocampus
Analyses adjusted for age, sex, body mass index, statin treatment, smoking, cholesterol level, history of vascular diseases, history of hypertension, history of
diabetes mellitus, and average blood pressure measures.
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Table 4| Microbleeds, infarcts, and white matter hyperintensities in three groups of visit-to-visit blood pressure variability. Values are odds
ratios (95% confidence intervals) unless stated otherwise
P valueThird of visit-to-visit blood pressure variabilityVariables
HighMiddleLow
(n=137)(n=191)(n=207)Systolic blood pressure
—16.3-64.412.3-16.20.7-12.2Range of SD (mm Hg)
0.391.30 (0.77 to 2.21)1.13 (0.69 to 1.85)1 (ref)Microbleeds
0.401.26 (0.78 to 2.04)0.95 (0.61 to 1.48)1 (ref)Infarcts
0.022.22 (1.09 to 4.54)1.34 (0.68 to 2.64)1 (ref)Cortical
0.970.84 (0.48 to 1.46)0.79 (0.48 to 1.31)1 (ref)Lacunar
0.987.79 (1.19)7.34 (1.08)8.12 (1.02)Mean (SE) WMH volume (mL)
(n=154)(n=166)(n=215)Diastolic blood pressure
—8.6-33.16.6-8.50-6.5Range of SD (mm Hg)
0.011.77 (1.06 to 2.96)1.75 (1.05 to 2.91)1 (ref)Microbleeds
0.431.32 (0.84 to 2.06)0.99 (0.63 to 1.56)1 (ref)Infarcts
0.022.19 (1.10 to 4.37)1.87 (0.93 to 3.76)1 (ref)Cortical
0.751.17 (0.70 to 1.95)0.95 (0.57 to 1.60)1 (ref)Lacunar
0.557.93 (1.10)8.27 (1.11)7.65 (1.05)Mean (SE) WMH volume (mL)
WMH=white matter hyperintensity.
Analyses were adjusted for age, sex, body mass index, statin treatment, smoking, cholesterol level, history of vascular diseases, history of hypertension, history
of diabetes mellitus, and average blood pressure measures.
Data for microbleeds, infarcts, and white matter hyperintensities were available for 535 participants.
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Figure
Scores for cognitive function in low, middle, and high thirds of variability in systolic and diastolic blood pressure between
measurements. Bars represent means (95% confidence intervals). Analyses were adjusted for age, sex, body mass index,
statin treatment, apolipoprotein E genotype, country, education, test version where appropriate, smoking, cholesterol level,
history of vascular diseases, history of hypertension, history of diabetes mellitus, and average blood pressure measures.
LDCT=letter-digit coding test, PLTi=immediate picture-word learning test, PLTd=delayed picture-word learning test
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